Employees Provident Fund Board’s Gilead Sciences GILD Stock Holding History

Employees Provident Fund Board’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.7M	Buy	488,657 +142,657	+41%	+$18.8M	0.35%	45
2026 Q1	$48.2M	Sell	346,000 -120,000	-26%	-$16.8M	0.36%	44
2025 Q4	$57.2M	Buy	466,000 +26,500	+6%	+$3.22M	0.42%	44
2025 Q3	$48.8M	Buy	439,500 +31,199	+8%	+$3.55M	0.39%	45
2025 Q2	$45.3M	Buy	408,301 +261,301	+178%	+$27.8M	0.39%	49
2025 Q1	$16.5M	Sell	147,000 -10,000	-6%	-$1.03M	0.19%	68
2024 Q4	$14.5M	Sell	157,000 -34,300	-18%	-$3.09M	0.18%	65
2024 Q3	$16M	Sell	191,300 -9,200	-5%	-$702K	0.22%	62
2024 Q2	$13.8M	Buy	200,500 +11,500	+6%	+$767K	0.22%	62
2024 Q1	$13.8M	Buy	189,000 +21,650	+13%	+$1.66M	0.24%	57
2023 Q4	$13.6M	Sell	167,350 -14,150	-8%	-$1.1M	0.26%	53
2023 Q3	$13.6M	Buy	181,500 +59,404	+49%	+$4.57M	0.31%	53
2023 Q2	$9.41M	Buy	122,096 +7,396	+6%	+$590K	0.22%	59
2023 Q1	$9.52M	Buy	114,700 +68,690	+149%	+$5.69M	0.25%	52
2022 Q4	$3.95M	Sell	46,010 -9,190	-17%	-$728K	0.11%	58
2022 Q3	$3.41M	Buy	55,200 +12,400	+29%	+$782K	0.1%	57
2022 Q2	$2.65M	Buy	42,800 +24,800	+138%	+$1.54M	0.06%	71
2022 Q1	$1.07M	Hold	18,000	–	–	0.02%	95
2021 Q4	$1.31M	Sell	18,000 -17,756	-50%	-$1.22M	0.02%	64
2021 Q3	$2.5M	Sell	35,756 -750,839	-95%	-$52.7M	0.04%	64
2021 Q2	$54.2M	Hold	786,595	–	–	0.89%	42
2021 Q1	$50.8M	Hold	786,595	–	–	0.87%	41
2020 Q4	$45.8M	Hold	786,595	–	–	0.78%	45
2020 Q3	$49.7M	Buy	786,595 +64,623	+9%	+$4.48M	1.04%	34
2020 Q2	$55.5M	Hold	721,972	–	–	1.26%	32
2020 Q1	$54M	Buy	721,972 +185,312	+35%	+$12.8M	1.47%	26
2019 Q4	$34.9M	Buy	536,660 +353,224	+193%	+$23M	0.74%	42
2019 Q3	$11.6M	Buy	+183,436	New	+$12M	0.31%	47
2017 Q3	–	Sell	-194,774	Closed	-$13.8M	–	47
2017 Q2	$13.8M	Sell	194,774 -1,372,122	-88%	-$91.3M	0.39%	49
2017 Q1	$106M	Buy	1,566,896 +283,183	+22%	+$19.9M	3.11%	11
2016 Q4	$91.9M	Buy	1,283,713 +166,278	+15%	+$12.4M	3.15%	11
2016 Q3	$88.4M	Buy	1,117,435 +280,807	+34%	+$22.8M	3.14%	13
2016 Q2	$69.8M	Buy	836,628 +354,335	+73%	+$31.4M	2.97%	15
2016 Q1	$44.3M	Buy	482,293 +75,435	+19%	+$6.8M	1.89%	23
2015 Q4	$41.2M	Sell	406,858 -34,951	-8%	-$3.64M	1.41%	23
2015 Q3	$43.4M	Buy	441,809 +259,600	+142%	+$28.8M	1.65%	26
2015 Q2	$21.3M	Sell	182,209 -18,157	-9%	-$1.98M	0.75%	37
2015 Q1	$19.7M	Sell	200,366 -117,205	-37%	-$11.9M	0.67%	40
2014 Q4	$29.9M	Buy	317,571 +215,113	+210%	+$22.2M	0.92%	37
2014 Q3	$10.9M	Sell	102,458 -12,017	-10%	-$1.18M	0.34%	51
2014 Q2	$9.49M	Buy	+114,475	New	+$8.91M	0.3%	50
2014 Q1	–	Sell	-102,194	Closed	-$7.68M	–	53
2013 Q4	$7.68M	Buy	+102,194	New	+$7.12M	0.23%	50

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Employees Provident Fund Board's GILD Position: Q2 2026 in Review

Employees Provident Fund Board increased its Gilead Sciences (GILD) stake by 41% in Q2 2026, buying an estimated $18.8M and bringing the position to 488,657 shares worth $61.7M. The position accounts for 0.35% of the portfolio, ranked #45.

Employees Provident Fund Board first reported a position in GILD in Q4 2013 and has held it in 42 quarters since. The position peaked at $106M in Q1 2017. 2,260 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Employees Provident Fund Board held 488,657 shares of Gilead Sciences worth $61.7M as of Q2 2026.
Employees Provident Fund Board bought 142,657 Gilead Sciences shares in Q2 2026, an estimated $18.8M.
Gilead Sciences made up 0.35% of Employees Provident Fund Board's portfolio in Q2 2026, its #45 holding.
Employees Provident Fund Board first reported a position in Gilead Sciences in Q4 2013 and has held it in 42 quarters since.
Employees Provident Fund Board's Gilead Sciences position peaked at $106M in Q1 2017.
2,260 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Employees Provident Fund Board's 13F filing for Q2 2026, filed 12 Aug 2026.